Phosphorylation of von Hippel-Lindau protein by checkpoint kinase 2 regulates p53 transactivation

Cell Cycle

Volumn 10, Issue 22, 2011, Pages 3920-3928

  Roe, Jae Seok ^a   Kim, Hwa Ryeon ^a   Hwang, In Young ^a   Ha, Nam Chul ^b   Kim, Seong Tae ^c   Cho, Eun Jung ^d   Youn, Hong Duk ^a,e  

^a Seoul National University College of Medicine   (South Korea)

^b Pusan National University   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

Chk2; DNA damage; p53; pVHL; Renal cell carcinoma

Indexed keywords

CHECKPOINT KINASE 2; PROTEIN P53; SERINE; VON HIPPEL LINDAU PROTEIN;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CHROMATIN; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; VON HIPPEL LINDAU DISEASE;

EID: 81855212680     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.22.18096     Document Type: Article

References (49)

1. Kaelin WG Jr. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 2009; 115:2262-72; PMID:19402056; DOI:10.1002/cncr.24232.
2. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29:625-34; PMID:19946328; DOI:10.1038/onc.2009.441.
3. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2:673-82; PMID:12209156; DOI:10.1038/nrc885.
4. Iliopoulos O, Ohh M, Kaelin WG Jr. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 1998; 95:11661-6; PMID:9751722; DOI:10.1073/pnas.95.20.11661.
5. Duan DR, Humphrey JS, Chen DY, Weng Y, Sukegawa J, Lee S, et al. Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci USA 1995; 92:6459-63; PMID:7604013; DOI:10.1073/pnas.92.14.6459.
6. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumor suppressor protein VHL targets HIF for oxygen-dependant proteolysis. Nature 1999; 399:271-5; PMID:10353251; DOI:10.1038/20459.
7. Cohen HT, McGovern FJ. Renal cell carcinoma. N Engl J Med 2005; 353:2477-90; PMID:16339096; DOI:10.1056/NEJMra043172.
8. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, et al. Germline mutations in the von-Hippel Lindau disease tumor suppressor gene: correlation with phenotype. Hum Mutat 1995; 5:66-75; PMID:7728151; DOI:10.1002/humu. 1380050109.
9. Neumann HP, Bender B. Genotype-phenotype correlation in von Hippel lindau disease. J Intern Med 1998; 243:541-5; PMID:9681856; DOI:10.1046/j.1365-2796. 1998.00336.x.
10. Czyzyk-Krzeska MF, Meller J. von Hippel-Lindau tumor suppressor: not only HIF's executioner. Trends Mol Med 2004; 10:146-9; PMID:15162797; DOI:10.1016/j.molmed.2004.02.004.
11. Dai C, Gu W. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med 2010; 16:528-36; PMID:20932800; DOI:10.1016/j.molmed.2010.09.002.
12. Mizutani Y, Nakanishi H, Yamamoto K, Li YN, Matsubara H, Mikami K, et al. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol 2005; 23:448-54; PMID:15572731; DOI:10.1200/JCO.2005.02.191.
13. Wu XX, Mizutani Y, Kakehi Y, Yoshida O, Ogawa O. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin. Cancer Res 2000; 60:2912-8; PMID:10850437.
14. Zantl N, Weirich G, Zall H, Seiffert BM, Fischer SF, Kirschnek S, et al. Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. Oncogene 2007; 26:7038-48; PMID:17486061; DOI:10.1038/sj.onc.1210510.
15. Roe JS, Kim HS, Lee SM, Kim ST, Cho EJ, Youn HD. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 2006; 22:395-405; PMID:16678111; DOI:10.1016/j.molcel.2006.04.006.
16. Roe JS, Youn HD. The positive regulation of p53 by the tumor suppressor VHL. Cell Cycle 2006; 5:2054-6; PMID:16969113; DOI:10.4161/cc.5.18.3247.
17. Semenza GL. VHL and p53: tumor suppressors team up to prevent cancer. Mol Cell 2006; 22:437-9; PMID:16713574; DOI:10.1016/j.molcel.2006.05.001.
18. Guo Y, Schoell MC, Freeman RS. The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIM (EL). Oncogene 2009; 28:1864-74; PMID:19305426; DOI:10.1038/onc.2009.35.
19. Roe JS, Kim HR, Hwang IY, Cho EJ, Youn HD. von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage. Oncogene 2011; 30:3127-38; PMID:21358672; DOI:10.1038/onc.2011.40.
20. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3:421-9; PMID:12781359; DOI:10.1016/S1535-6108(03) 00110-7.
21. O'Neill T, Giarratani L, Chen P, Iyer L, Lee CH, Bobiak M, et al. Determination of substrate motifs for human Chk1 and hCds1/Chk2 by the oriented peptide library approach. J Biol Chem 2002; 277:16102-15; PMID:11821419; DOI:10.1074/jbc.M111705200.
22. Stolle C, Glenn G, Zbar B, Humphrey JS, Choyke P, Walther M, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998; 12:417-23; PMID:9829911; DOI:10.1002/(SICI) 1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K.
23. Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW, et al. Structural basis for the recognition of hydroxyproline in HIF-1alpha by pVHL. Nature 2002; 417:975-8; PMID:12050673; DOI:10.1038/nature00767.
24. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr, Pavletich NP. Structure of an HIF-1alpha-pVHL complex: hydroxyproline recognition in signaling. Science 2002; 296:1886-9; PMID:12004076; DOI:10.1126/science.1073440.
25. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 1997; 89:1175-84; PMID:9215639; DOI:10.1016/S0092-8674(00)80304-9.
26. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90:595-606; PMID:9288740; DOI:10.1016/S0092-8674(00)80521-8.
27. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 2006; 24:841-51; PMID:17189187; DOI:10.1016/j.molcel.2006.11.026.
28. Tang Y, Luo J, Zhang W, Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell cycle arrest and apoptosis. Mol Cell 2006; 24:827-39; PMID:17189186; DOI:10.1016/j.molcel.2006.11.021.
29. Jenkins LM, Yamaguchi H, Hayashi R, Cherry S, Tropea JE, Miller M, et al. Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation. Biochemistry 2009; 48:1244-55; PMID:19166313; DOI:10.1021/bi801716 h.
30. Polley S, Guha S, Roy NS, Kar S, Sakaguchi K, Chuman Y, et al. Differential recognition of phosphorylated transactivation domains of p53 by different p300 domains. J Mol Biol 2008; 376:8-12; PMID:18155245; DOI:10.1016/j.jmb.2007.11.082.
31. Foy RL, Song IY, Chitalia VC, Cohen HT, Saksouk N, Cayrou C, et al. Role of Jade-1 in the histone acetyltransferase (HAT) HBO1 complex. J Biol Chem 2008; 283:28817-26; PMID:18684714; DOI:10.1074/jbc.M801407200.
32. Zhou MI, Wang H, Foy RL, Ross JJ, Cohen HT. Tumor suppressor von Hippel-Lindau (VHL) stabilization of Jade-1 protein occurs through plant homeodomains and is VHL mutation dependent. Cancer Res 2004; 64:1278-86; PMID:14973063; DOI:10.1158/0008-5472.CAN-03-0884.
33. Berkovich E, Monnat RJ Jr, Kastan MB. Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repair. Nat Cell Biol 2007; 9:683-90; PMID:17486112; DOI:10.1038/ncb1599.
34. Berkovich E, Monnat RJ Jr, Kastan MB. Assessment of protein dynamics and DNA repair following generation of DNA double-strand breaks at defined genomic sites. Nat Protoc 2008; 3:915-22; PMID:18451799; DOI:10.1038/nprot.2008.54.
35. McCord RA, Michishita E, Hong T, Berber E, Boxer LD, Kusumoto R, et al. SIRT6 stabilizes DNA-dependent protein kinase at chromatin for DNA double-strand break repair. Aging (Albany NY) 2009; 1:109-21; PMID:20157594.
36. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126:107-20; PMID:16839880; DOI:10.1016/j.cell.2006.05.036.
37. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, et al. p53 regulates mitochondrial respiration. Science 2006; 312:1650-3; PMID:16728594; DOI:10.1126/science.1126863.
38. Murr R, Loizou JI, Yang YG, Cuenin C, Li H, Wang ZQ, et al. Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks. Nat Cell Biol 2006; 8:91-9; PMID:16341205; DOI:10.1038/ncb1343.
39. Tominaga K, Morisaki H, Kaneko Y, Fujimoto A, Tanaka T, Ohtsubo M, et al. Role of human Cds1 (Chk2) kinase in DNA damage checkpoint and its regulation by p53. J Biol Chem 1999; 274:31463-7; PMID:10531348; DOI:10.1074/jbc.274.44. 31463.
40. Chehab NH, Malikzay A, Appel M, Halazonetis TD. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 2000; 14:278-88; PMID:10673500.
41. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000; 14:289-300; PMID:10673501.
42. Bruno T, De-Nicola F, Iezzi S, Lecis D, D'Angelo C, Di-Padova M, et al. Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. Cancer Cell 2006; 10:473-86; PMID:17157788; DOI:10.1016/j.ccr.2006.10.012.
43. Unwin RD, Craven RA, Harnden P, Hanrahan S, Totty N, Knowles M, et al. Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 2003; 3:1620-32; PMID:12923786; DOI:10.1002/pmic.200300464.
44. Craven RA, Hanrahan S, Totty N, Harnden P, Stanley AJ, Maher ER, et al. Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma. Proteomics 2006; 6:3880-93; PMID:16739133; DOI:10.1002/pmic. 200500811.
45. Hervouet E, Demont J, Pecina P, Vojtísková A, Houstek J, Simonnet H, et al. A new role for the von Hippel-Lindau tumor suppressor protein: stimulation of mitochondrial oxidative phosphorylation complex biogenesis. Carcinogenesis 2005; 26:531-9; PMID:15604095; DOI:10.1093/carcin/ bgi001.
46. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007; 11:407-20; PMID:17482131; DOI:10.1016/j.ccr.2007.04.001.
47. Favier J, Brière JJ, Burnichon N, Rivière J, Vescovo L, Benit P, et al. The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS ONE 2009; 4:7094; PMID:19763184; DOI:10.1371/journal. pone.0007094.
48. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005; 7:77-85; PMID:15652751; DOI:10.1016/j.ccr.2004.11.022.
49. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998; 282:1893-7; PMID:9836640; DOI:10.1126/science.282.5395.1893.